Harmony Biosciences Holdings, Inc.

HRMY · XNAS

CIK 1802665fmd_0EY7KD0RD4M1DKY3KGD1PEJQARManufacturing · Pharmaceutical PreparationsTemplate: Standard

Coverage: Jan 01, 2019 to Sep 30, 2026, 29 periods

Income Statement · Annual · Millions · USD
Line item	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Total revenues	6	160	305	438	582	715	868
Cost of revenue	2	28	56	83	121	157	198
Gross profit	4	132	250	354	461	558	670
Research and development	70	19	30	71	76	146	190
Selling, general and administrative	81	96	132	163	193	221	272
Total operating expenses	150	115	162	234	269	367	462
Operating income	(146)	17	88	120	192	191	208
Interest expense	7	29	24	19	24	17	15
Other non-operating income (expense)	–	(3)	0	0	0	(0)	(1)
Income before taxes	(152)	(37)	37	105	173	192	215
Income tax expense	–	–	3	(77)	45	46	56
Net income from continuing operations	–	–	35	181	129	145	159
Net income	(152)	(37)	35	181	129	145	159
Net income to common shareholders	(187)	(64)	35	181	129	–	–